Perspectives of metformin use in endometrial cancer and other gynaecological malignancies
- 18 November 2021
- journal article
- other
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 30 (4) , 359-367
Abstract
Insulin resistance and hyperinsulinemia play a key role in type 1 endometrial cancer pathogenesis. Most of these cancers develop on a background of overweight or type 2 diabetes mellitus (T2DM). One of the medications widely used in the treatment of T2DM is biguanide derivative, metformin, which exerts promising anticancer properties principally through activation of adenosine monophosphate kinase (AMPK) and inhibition of mammalian target of rapamycin (mTOR) pathways. Many epidemiological studies on diabetic patients show potential preventative role of metformin in endometrial cancer patients, but data regarding its therapeutic role is still limited. So far, most of attention has been paid to the concept of metformin use in fertility sparing treatment of early-stage cancer. Another investigated alternative is its application in patients with primary advanced or recurrent disease. In this review we present the latest data on clinical use of metformin in endometrial cancer patients and potential underlying mechanisms of its activity. Finally, we present some most important clinical information regarding metformin efficacy in other gynaecological malignancies, mainly breast and ovarian cancer.Keywords
Funding Information
- Medical University of Lublin (120/2020rtd)
This publication has 103 references indexed in Scilit:
- Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent MannersPLOS ONE, 2013
- The Role of Preexisting Diabetes Mellitus on Incidence and Mortality of Endometrial CancerInternational Journal of Gynecological Cancer, 2013
- Metformin intake is associated with better survival in ovarian cancerCancer, 2012
- Metformin impairs the growth of liver kinase B1-intact cervical cancer cellsGynecologic Oncology, 2012
- Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathwayGynecologic Oncology, 2012
- Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and ChemosensitivityObstetrics & Gynecology, 2012
- Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2011
- Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancerCancer, 2011
- Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategyGynecologic Oncology, 2010
- Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast CancerJournal of Clinical Oncology, 2009